JP5562939B2 - アクチン細胞骨格再編成及び細胞間ギャップ形成調節の方法 - Google Patents

アクチン細胞骨格再編成及び細胞間ギャップ形成調節の方法 Download PDF

Info

Publication number
JP5562939B2
JP5562939B2 JP2011504178A JP2011504178A JP5562939B2 JP 5562939 B2 JP5562939 B2 JP 5562939B2 JP 2011504178 A JP2011504178 A JP 2011504178A JP 2011504178 A JP2011504178 A JP 2011504178A JP 5562939 B2 JP5562939 B2 JP 5562939B2
Authority
JP
Japan
Prior art keywords
group
cells
compound
oxygen atom
organ
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011504178A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011516572A5 (enExample
JP2011516572A (ja
Inventor
マイケル エガン トーマス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of JP2011516572A publication Critical patent/JP2011516572A/ja
Publication of JP2011516572A5 publication Critical patent/JP2011516572A5/ja
Application granted granted Critical
Publication of JP5562939B2 publication Critical patent/JP5562939B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011504178A 2008-04-09 2009-04-09 アクチン細胞骨格再編成及び細胞間ギャップ形成調節の方法 Expired - Fee Related JP5562939B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4358608P 2008-04-09 2008-04-09
US61/043,586 2008-04-09
PCT/US2009/040098 WO2009126822A2 (en) 2008-04-09 2009-04-09 Methods of regulating actin cytoskeletal rearrangement and intercellular gap formation

Publications (3)

Publication Number Publication Date
JP2011516572A JP2011516572A (ja) 2011-05-26
JP2011516572A5 JP2011516572A5 (enExample) 2012-05-24
JP5562939B2 true JP5562939B2 (ja) 2014-07-30

Family

ID=41162617

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011504178A Expired - Fee Related JP5562939B2 (ja) 2008-04-09 2009-04-09 アクチン細胞骨格再編成及び細胞間ギャップ形成調節の方法

Country Status (14)

Country Link
US (1) US8809303B2 (enExample)
EP (1) EP2268286B1 (enExample)
JP (1) JP5562939B2 (enExample)
KR (1) KR20100135886A (enExample)
CN (1) CN102083443B (enExample)
AU (1) AU2009234156A1 (enExample)
BR (1) BRPI0911195A2 (enExample)
CA (1) CA2721082A1 (enExample)
EA (1) EA201001450A1 (enExample)
ES (1) ES2569608T3 (enExample)
IL (1) IL208565A0 (enExample)
MX (1) MX2010011050A (enExample)
WO (1) WO2009126822A2 (enExample)
ZA (1) ZA201007735B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009126822A2 (en) 2008-04-09 2009-10-15 The University Of North Carolina At Chapel Hill Methods of regulating actin cytoskeletal rearrangement and intercellular gap formation
CA2757998A1 (en) * 2009-04-09 2010-10-14 The University Of North Carolina At Chapel Hill Methods of treating edema related to ischemia-reperfusion
CN103160570A (zh) * 2011-12-09 2013-06-19 彩虹天健康科技研究(北京)有限责任公司 Unc-51激酶和pp1磷酸酶相互作用机制的发现
CA3090271A1 (en) 2018-02-12 2019-08-15 Inimmune Corporation Toll-like receptor ligands
CN108836971B (zh) * 2018-08-16 2020-10-30 青岛大学 Ws6对小梁网细胞肌动蛋白形成的影响

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5628984A (en) 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
US5843024A (en) * 1996-05-17 1998-12-01 Breonics, Inc. Solution and process for resuscitation and preparation of ischemically damaged tissue
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6013640A (en) * 1998-08-21 2000-01-11 Ribi Immunochem Research, Inc. Phosphoglycolipid and methods for its use
CN1411504A (zh) 2000-01-19 2003-04-16 查珀尔希尔-北卡罗莱纳大学 肝脏组织来源
US6699846B2 (en) 2000-03-17 2004-03-02 Corixa Corporation Mono- and disaccharides for the treatment of nitric oxide related disorders
AU2003242320A1 (en) 2002-06-13 2003-12-31 Mitsubishi Pharma Corporation Medicine for prevention of and/or treatment for liver inshemiareperfusion injury and protective agent for transplant liver
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
JP2007514648A (ja) 2003-10-24 2007-06-07 エーザイ株式会社 Ｔｏｌｌ−ｌｉｋｅｒｅｃｅｐｔｏｒ２に関連する疾患及び状態を治療するための化合物及び方法
US7928132B2 (en) 2004-08-06 2011-04-19 Ohio University Methods for the amelioration of episodes of acute or chronic ulcerative colitis
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
WO2005117975A2 (en) 2004-05-28 2005-12-15 Cedars-Sinai Medical Center Methods for treating vascular disease
ITMI20060530A1 (it) 2006-03-22 2007-09-23 Univ Milano Bicocca Antinfiammatori a struttura monosaccaridica
AU2008285626B2 (en) 2007-08-03 2013-09-12 Neuramedy Co., Ltd. Use of TLR-2 antagonists for treatment of reperfusion injury and tissue damage
WO2009126822A2 (en) 2008-04-09 2009-10-15 The University Of North Carolina At Chapel Hill Methods of regulating actin cytoskeletal rearrangement and intercellular gap formation
CA2757998A1 (en) * 2009-04-09 2010-10-14 The University Of North Carolina At Chapel Hill Methods of treating edema related to ischemia-reperfusion

Also Published As

Publication number Publication date
EA201001450A1 (ru) 2011-08-30
WO2009126822A9 (en) 2009-12-17
CA2721082A1 (en) 2009-10-15
EP2268286B1 (en) 2016-04-06
CN102083443A (zh) 2011-06-01
BRPI0911195A2 (pt) 2017-06-20
ES2569608T3 (es) 2016-05-11
CN102083443B (zh) 2014-01-15
JP2011516572A (ja) 2011-05-26
IL208565A0 (en) 2010-12-30
EP2268286A4 (en) 2011-10-12
WO2009126822A2 (en) 2009-10-15
US20110053871A1 (en) 2011-03-03
KR20100135886A (ko) 2010-12-27
EP2268286A1 (en) 2011-01-05
ZA201007735B (en) 2013-04-24
AU2009234156A1 (en) 2009-10-15
US8809303B2 (en) 2014-08-19
MX2010011050A (es) 2010-11-01

Similar Documents

Publication Publication Date Title
Moskowitzova et al. Mitochondrial transplantation prolongs cold ischemia time in murine heart transplantation
US20120064044A1 (en) Methods of treating edema related to ischemia-reperfusion
JP5562939B2 (ja) アクチン細胞骨格再編成及び細胞間ギャップ形成調節の方法
JP7672127B2 (ja) 細胞凍結保存用溶液およびその利用
TW201402136A (zh) 含有海藻糖之預防肺栓塞用哺乳動物細胞懸浮液
US20060014709A1 (en) Drug or cosmetic
US10828338B2 (en) Methods for improving cognition and slowing cognitive impairment using nonviable lyophilized pluripotent stem cells
TW201406402A (zh) 含有聚葡糖之預防肺栓塞用哺乳動物細胞懸浮液
US20210368780A1 (en) Compositions for maintaining the viability of living and static biological material, methods of making and the uses thereof
US20210000877A1 (en) Method For Upregulation Of Thioredoxin Expression In Stem Cells
US20140228407A1 (en) Tetra-pyridine compounds and composition for protecting cells, tissues and organs against ischemia-reperfusion injury
EP1100539B1 (de) Wirkstoffkombination insbesondere zur prophylaxe und therapie von ischämischen organschäden und reperfusionssyndromen
US6313104B1 (en) Organoprotective solutions
McGrath A New Series of" Pro-CPAs," Amino-Acid Derivatized Sugar Alcohols for Cell Cryopreservation
Wada et al. Effects of Perfluorochemical‐Based Artificial Blood Compounds in Discordant Xenotransplantation
JP2024024327A (ja) 細胞の投与液
JP2022083279A (ja) 腎臓保護用の組成物
JP2022020549A (ja) 細胞製剤
JPWO2007099711A1 (ja) 分化誘導剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120328

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131008

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140107

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140207

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140307

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140318

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140609

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140611

R150 Certificate of patent or registration of utility model

Ref document number: 5562939

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees